The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.

ABSTRACT:

Background

Since June 2019, cancer genomic profiling (CGP) tests have been reimbursed by the National Health Insurance system in Japan, with restrictions for government-designated hospitals with a molecular tumor board composed of multidisciplinary specialists, known as an expert panel (EP). The standardization of EPs is a critical challenge for implementing precision oncology in the clinical setting.

Methods

Data on consecutive cases who underwent the CGP tests at 11 core hospitals between June 2019 and January 2020 were collected. We evaluated the proportions of cases that received genomically matched treatments, including investigational new drugs (INDs) based on CGP results, and/or for which genetic counseling was recommended. Two simulated cases were annotated by each E

SUBMITTER: Sunami K 

PROVIDER: S-EPMC7895780 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature